Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 7/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 7/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1601602 | 0.85 | HTT (0.66) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4500500 | 0.84 | HTT (0.61) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3459886 | 0.82 | HTT (0.83) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL29742388 | 0.82 | HTT (0.83) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3460628 | 0.82 | HTT (0.83) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2465110 | 0.82 | HTT (0.83) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6570868 | 0.78 | LMNA (0.69) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL19630401 | 0.77 | HTT (0.66) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10528660 | 0.77 | HTT (0.66) | HTTPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8160654 | 0.77 | HTT (0.70) | HTTPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633716-A4 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-26 | — | — | EP | claimed |
| US-7129264-B2 | Biarylmethyl indolines and indoles as antithromboembolic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-31 | — | — | US | claimed |
| EP-1633716-A2 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-03-15 | — | — | EP | claimed |
| WO-2004094372-A2 | COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | claimed |
| EP-1633716-A4 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2008-03-26 | — | — | EP | disclosed |
| US-7129264-B2 | Biarylmethyl indolines and indoles as antithromboembolic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1633716-A2 | BIARYLMETHYL INDOLINES, INDOLES AND TETRAHYDROQUINOLINES, USEFUL AS SERINE PROTEASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004094372-A2 | COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220206-A1 | Biarylmethyl indolines, indoles and tetrahydroquinolines, useful as serine protease inhibitors | TFPI, TFPI2, F2 | HTT 4087/4885PDE4A 2922/4885PDE4B 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.